Search the site

Research breakthrough gives hope to children with rare and undiagnosed diseases

A complex five-year experiment which cracked the code of a genetic mystery has paved the way for faster and more accurate diagnoses of the most rare and unknown diseases affecting children.

Prestigious fellowship for pioneering researcher

Aleksandra Filipovska has been elected a Fellow of the Australian Academy of Health and Medical Sciences.

The Kids Research Institute Australia leader named finalist in nation’s top science prizes

One of Australia’s leading infectious disease experts, Associate Professor Asha Bowen, has been announced as a finalist for the country’s leading national science awards – the Australian Museum Eureka Prizes.

National honour for The Kids Director

Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).

Wesfarmers donates five million for medical research

Wesfarmers will kick off Telethon 2013 with a $5 million donation over four years to establish the Wesfarmers Centre of Vaccines & Infectious Diseases.

Celebrating 20 years of meningitis awareness

Australian charity celebrates 20 years of providing meningitis awareness and marks World Meningitis Day with footy star

NeXXstep Study

Help us discover a way to expand protection for the next generation.

Resources

Wesfarmers Centre of Vaccines & Infectious Diseases resources

10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine versus 13-valent pneumococcal conjugate vaccine as a booster dose to broaden and strengthen protection from otitis media in Australian Aboriginal children: study protocol

18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels

Study protocol for controlled human infection for penicillin G against Streptococcus pyogenes: a double-blinded, placebo-controlled, randomised trial to determine the minimum concentration required to prevent experimental pharyngitis (the CHIPS trial)

Regular intramuscular benzathine penicillin G injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. As the pharmacological correlate of protection remains unknown, it is difficult to recommend changes to this established regimen. Determining the minimum effective penicillin exposure required to prevent Streptococcus pyogenes infection will accelerate development of new long-acting penicillins for RHD prevention as well as inform opportunities to improve existing regimens. The CHIPS trial will address this knowledge gap by directly testing protection afforded by different steady state plasma concentrations of penicillin in an established model of experimental human S. pyogenes pharyngitis.